Open AccessS183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB
Author(s) -
Donk N. W.,
Bahlis N.,
Mateos M.V.,
Weisel K.,
Dholaria B.,
Garfall A. L.,
Goldschmidt H.,
Martin T. G.,
Morillo D.,
Reece D. E.,
Hurd D.,
RodríguezOtero P.,
Bhutani M.,
D'Souza A.,
Oriol A.,
Askari E.,
SanMiguel J. F.,
Kortüm K. M.,
Vishwamitra D.,
Xin Wang Lin S.,
Prior T. J.,
Vandenberk L.,
Smit M.A. D.,
Goldberg J. D.,
Wäsch R.,
Chari A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843624.82943.92
Subject(s) - daratumumab , medicine , tumor lysis syndrome , oncology , combination therapy , multiple myeloma , cd8 , immune system , immunology , lenalidomide , chemotherapy